Why the study?
Eligibility for vericiguat in a real-world heart failure population based on trial, guideline, and label criteria remained to be determined.
What proportion of real-world HFrEF patients are eligible for vericiguat according to trial, guideline, and label criteria?
What proportion of real-world HFrEF patients are eligible for vericiguat according to trial, guideline, and label criteria?
In a real-world HFrEF cohort, nearly half of patients are eligible for vericiguat based on guidelines and labelling, compared to only one-fifth based on strict trial criteria.
No takes yet. Share an insight, caveat, or question.
Eligibility varies by criteria in real-world HFrEF; leaves open optimal selection and requires prospective validation before practice change.
Nguyen et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: